Clinical Trials
178
Trial Phases
5 Phases
Drug Approvals
120
Drug Approvals
Rivastigmine Hydrogen Tartrate Capsules
- Product Name
- 重酒石酸卡巴拉汀胶囊
- Approval Number
- 国药准字HJ20181097
- Approval Date
- May 13, 2022
Rivastigmine Hydrogen Tartrate Capsules
- Product Name
- 重酒石酸卡巴拉汀胶囊
- Approval Number
- 国药准字HJ20181098
- Approval Date
- May 13, 2022
Paliperidone Extended-release Tablets
- Product Name
- 帕利哌酮缓释片
- Approval Number
- 国药准字HJ20220013
- Approval Date
- Mar 1, 2022
Paliperidone Extended-release Tablets
- Product Name
- 帕利哌酮缓释片
- Approval Number
- 国药准字HJ20220014
- Approval Date
- Mar 1, 2022
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (159 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
- Conditions
- Moderate to Severe Genital Psoriasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 192
- Registration Number
- NCT06611163
- Locations
- 🇺🇸
Medical Dermatology Specialists, Phoenix, Arizona, United States
🇺🇸Smary Cures Clinical Research, Anaheim, California, United States
🇺🇸California Dermatology & Clinical Research Institute, Encinitas, California, United States
A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 10
- Registration Number
- NCT06425900
- Locations
- 🇺🇸
Dermatology Consulting Services, PLLC, High Point, North Carolina, United States
A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 50
- Registration Number
- NCT06415292
- Locations
- 🇺🇸
Dermatology Consulting Services, PLLC, High Point, North Carolina, United States
A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 10
- Registration Number
- NCT06415305
- Locations
- 🇺🇸
Skin Sciences, PLLC, Louisville, Kentucky, United States
A Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 40
- Registration Number
- NCT06415279
- Locations
- 🇺🇸
Dermatology Consulting Services, PLLC, High Point, North Carolina, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 12
- Next
News
Sun Pharma's ILUMYA Achieves Primary Endpoints in Two Phase 3 Psoriatic Arthritis Trials
Sun Pharmaceutical Industries announced that tildrakizumab (ILUMYA) 100 mg successfully met primary endpoints in two Phase 3 clinical studies for active psoriatic arthritis treatment.
Sun Pharma Names Kirti Ganorkar as Managing Director in Major Leadership Transition
Kirti Ganorkar, a 29-year Sun Pharma veteran, will become Managing Director on September 1, 2025, succeeding founder Dilip Shanghvi who transitions to Executive Chairman.
Sun Pharma Discontinues Psoriasis and Eczema Drug SCD-044 After Phase 2 Trial Failures
Sun Pharma's experimental oral drug SCD-044 (Vibozilimod) failed to meet primary endpoints in Phase 2 trials for both psoriasis and atopic dermatitis, missing the 75% improvement target in PASI and EASI scores at 16 weeks.
FDA Approves Sun Pharma's Next-Generation LED BLU-U Device for Actinic Keratosis Treatment
The FDA has granted premarket approval for Sun Pharma's next-generation BLU-U Blue Light Photodynamic Therapy Illuminator, featuring LED panels instead of fluorescent tubes for treating actinic keratosis.
Sun Pharma Increases Investment in US-Based Pharmazz to Expand Specialty Therapeutics Portfolio
Sun Pharma has signed an agreement to invest up to $25 million in US-based Pharmazz, increasing its stake to approximately 22.7% on a fully diluted basis.
Sun Pharma and Moebius Medical's MM-II Shows Promising Results for Knee Osteoarthritis in Phase 2b Trial
A single injection of MM-II, a novel non-opioid treatment developed by Sun Pharma and Moebius Medical, demonstrated clinically meaningful pain relief for knee osteoarthritis lasting up to 26 weeks in a Phase 2b trial involving 397 patients.
Sun Pharma Launches Fexuclue in India: A Novel Treatment for Erosive Esophagitis
Sun Pharmaceutical has introduced Fexuclue (fexuprazan 40 mg), a novel potassium-competitive acid blocker, as a new treatment option for adults with all grades of erosive esophagitis in India.
Fortress Biotech Reports Strong 2024 Results with Two FDA Approvals and Strategic Acquisition Deal
Fortress Biotech secured FDA approvals for two key products in Q4 2024: Emrosi for inflammatory lesions of rosacea and UNLOXCYT for advanced cutaneous squamous cell carcinoma, with commercial launch of Emrosi already underway.
Lupin Launches First Generic Xarelto in US Market Despite Ongoing Patent Litigation
Lupin has begun rolling out the first generic version of the blockbuster anticoagulant Xarelto (rivaroxaban) in the US market after the Patent Trial and Appeal Board invalidated a key patent.
Sun Pharma to Acquire Checkpoint Therapeutics in $355 Million Deal for Novel Skin Cancer Treatment
Sun Pharmaceutical Industries will acquire Checkpoint Therapeutics for $355 million upfront, with stockholders receiving $4.10 per share plus a contingent value right worth up to $0.70 per share based on European approval milestones.